Key clinical point: CLL relapsed after therapy with a B-cell receptor signaling inhibitor has a rapidly progressive course, requiring quick ramp up of venetoclax.
Major finding: All patients reached the target dose of venetoclax, with only two cases of manageable clinical tumor lysis syndrome.
Study details: Retrospective analysis of outcomes for 15 patients with chronic lymphocytic leukemia relapsed after treatment with a B-cell receptor signaling inhibitor.
Disclosures: The study was internally funded. Dr. Awan receives research funding from Gilead, Pharmacyclics. AbbVie and Janssen.
Source: Awan F et al. European Hematology Association 2018 Annual Congress. Abstract PF357
Awan F et al. European Hematology Association 2018 Annual Congress. Abstract PF357
This Week's Must Reads
Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.
Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.
Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.
Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.
Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.
Must Reads in CLL
Uninterrupted ibrutinib with CAR T may boost outcomes in CLL , Gauthier J et al. ASH 2018, Abstract 299
The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018
Ibrutinib dosing changes and the impact on survival, Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
First-line ibrutinib has long-term survival benefit, Barr PM et al. Haematologica. 2018;103(9):1502-10.